Editas Medicine

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell EDIT and other ETFs, options, and stocks.

About EDIT

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9).

CEO

Gilmore O’Neill

CEOGilmore O’Neill

Employees

246

Employees246

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

2013

Founded2013

Employees

246

Employees246

EDIT Key Statistics

Market cap

245.93M

Market cap245.93M

Price-Earnings ratio

-1.06

Price-Earnings ratio-1.06

Dividend yield

—

Dividend yield—

Average volume

2.34M

Average volume2.34M

High today

$3.09

High today$3.09

Low today

$2.73

Low today$2.73

Open price

$3.07

Open price$3.07

Volume

1.84M

Volume1.84M

52 Week high

$4.19

52 Week high$4.19

52 Week low

$0.9101

52 Week low$0.9101

EDIT News

TipRanks 3d

Editas Medicine price target raised to $5 from $3 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Editas Medicine (EDIT) to $5 from $3 and keeps a Buy rating on the shares following the Q2 report. The firm ci...

Analyst ratings

47%

of 15 ratings

Buy

40%

Hold

46.7%

Sell

13.3%

People also own

Based on the portfolios of people who own EDIT. This list is generated using Robinhood data, and it’s not a recommendation.

CRISPR

Intellia Therapeutics